Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aeterna Zentaris Inc (AEZS.TO)

Aeterna Zentaris Inc (AEZS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aeterna Zentaris Inc c/o Norton Rose Fulbright Canada LLP 222 Bay Street, Suite 3000 Toronto ON M5K 1E7 CAN

https://www.zentaris.com P: 843-900-3223 F: 416-216-4000

Description:

AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna's lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.

Key Statistics

Overview:

Market Capitalization, $K 18,340
Shares Outstanding, K 3,062
Annual Sales, $ 4,498 K
Annual Net Income, $ -16,552 K
Last Quarter Sales, $ 4 K
Last Quarter Net Income, $ -5,752 K
60-Month Beta 1.08
% of Institutional Shareholders 0.10%

Growth:

1-Year Return -57.30%
3-Year Return -94.21%
5-Year Return -98.30%
5-Year Revenue Growth -3.64%

Per-Share Information:

Most Recent Earnings -0.85 on 05/16/24
Next Earnings Date 08/14/24
Earnings Per Share ttm -3.18
EPS Growth vs. Prev Year -379.11%
Most Recent Dividend 4,949.990 on 08/11/99
Next Ex-Dividends Date 08/11/99
Dividend Payable Date 01/01/70
Dividend Payout Ratio 0.00%
Most Recent Split 0-1 on 06/07/24

AEZS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -81.71%
Return-on-Assets % -43.45%
Profit Margin % -367.99%
Debt/Equity 0.01
Price/Sales 3.76
Price/Book 0.71
Book Value/Share 5.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar